About this Research Topic
Arterial hypertension and cancer are two of the most important causes of mortality in the world; correlations between these two clinical entities are complex and various. Cancer therapy using old (e.g., mitotic spindle poisons) as well as new (e.g. monoclonal antibody) drugs may cause arterial hypertension through different mechanisms; sometimes the increase of blood pressure levels may be responsible for chemotherapy withdrawal. Among newer cancer therapies, drugs interacting with the VEGF (vascular endothelial growth factors) pathways are the most frequently involved in hypertension development. However, many retrospective studies have suggested a relationship between antihypertensive treatment and the risk of cancer, raising vast public concern.
This Research Topic aims to evaluate the role of chemotherapy in the pathogenesis of hypertension, to evaluate the general rules of arterial hypertension management in this field and finally to evaluate the effects of antihypertensive therapy on cancer disease.
Potential sub-topics include:
1) Clinical, cellular and molecular interaction between cancer therapy and arterial hypertension (e.g. cancer and neurological disorders).
2) Lifestyle (e.g. stress, diet and exercise) role in arterial hypertension related to cancer therapy.
3) Cardiovascular events in patients undergoing treatment with cancer drugs (such as Anti VEGF, carfilzomib etc).
4) Cardiovascular risk stratification in patient with
5) Relationship between antihypertensive treatment and risk of cancer.
Human, animal and in vitro models are welcome. Original Research Articles and Reviews are welcomed.
This Research Topic aims to evaluate the role of chemotherapy in the pathogenesis of hypertension, to evaluate the general rules of arterial hypertension management in this field and finally to evaluate the effects of antihypertensive therapy on cancer disease.
Potential sub-topics include:
1) Clinical, cellular and molecular interaction between cancer therapy and arterial hypertension (e.g. cancer and neurological disorders).
2) Lifestyle (e.g. stress, diet and exercise) role in arterial hypertension related to cancer therapy.
3) Cardiovascular events in patients undergoing treatment with cancer drugs (such as Anti VEGF, carfilzomib etc).
4) Cardiovascular risk stratification in patient with
5) Relationship between antihypertensive treatment and risk of cancer.
Human, animal and in vitro models are welcome. Original Research Articles and Reviews are welcomed.
Keywords: Arterial Hypertension, Cancer, VEGF inhibitors, vascular toxicity, heart toxicity
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
